Terlipressin

Terlipressin
Clinical data
AHFS/Drugs.com	International Drug Names
Routes of; administration	IV
ATC code	H01BA04 (WHO) ;
Pharmacokinetic data
Protein binding	~30%
Identifiers
	IUPAC name 1-{[(4R,7S,10S,13S,16S,19R)-19-{[({[(aminoacetyl)amino]acetyl}amino)acetyl]amino}-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-4-yl]carbonyl}-L-prolyl-N-(2-amino-2-oxoethyl)-L-lysinamide;
CAS Number	14636-12-5 ;
PubChem CID	72081;
DrugBank	DB02638 ;
ChemSpider	65067 ;
UNII	7Z5X49W53P;
KEGG	D06672 ;
CompTox Dashboard (EPA)	DTXSID7048952 ;
ECHA InfoCard	100.035.149
Chemical and physical data
Formula	C52H74N16O15S2
Molar mass	1227.38 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(N)CNC(=O)[C@@H](NC(=O)[C@H]4N(C(=O)[C@H]1NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1)Cc2ccc(O)cc2)Cc3ccccc3)CCC(=O)N)CC(=O)N)CCC4)CCCCN;
	InChI InChI=1S/C52H74N16O15S2/c53-17-5-4-9-31(45(76)60-23-41(57)72)63-51(82)38-10-6-18-68(38)52(83)37-27-85-84-26-36(61-44(75)25-59-43(74)24-58-42(73)22-54)50(81)65-34(20-29-11-13-30(69)14-12-29)48(79)64-33(19-28-7-2-1-3-8-28)47(78)62-32(15-16-39(55)70)46(77)66-35(21-40(56)71)49(80)67-37/h1-3,7-8,11-14,31-38,69H,4-6,9-10,15-27,53-54H2,(H2,55,70)(H2,56,71)(H2,57,72)(H,58,73)(H,59,74)(H,60,76)(H,61,75)(H,62,78)(H,63,82)(H,64,79)(H,65,81)(H,66,77)(H,67,80)/t31-,32-,33-,34-,35-,36-,37-,38-/m0/s1 ; Key:BENFXAYNYRLAIU-QSVFAHTRSA-N ;
	(verify)

Terlipressin (trade names Teripress by New Medicon Pharma and Glypressin by Ferring Pharmaceuticals) is an analogue of vasopressin used as a vasoactive drug in the management of low blood pressure. It has been found to be effective when norepinephrine does not help. It also helps prevent urination.[1]

Indications for use include norepinephrine-resistant septic shock[2] and hepatorenal syndrome.[3] In addition, it is used to treat bleeding esophageal varices.[4]

Availability

Terlipressin is currently not available in the United States,[5] or Canada,[6] but it is available in New Zealand,[7] Australia, much of Europe,[8] India, Pakistan & UAE.

Contraindications

Terlipressin must not be used during pregnancy.

References

Kam, P. C. A.; Williams, S.; Yoong, F. F. Y. (2004). "Vasopressin and terlipressin: pharmacology and its clinical relevance". Anaesthesia. 59 (10): 993–1001. doi:10.1111/j.1365-2044.2004.03877.x. ISSN 1365-2044.
O'Brien A, Clapp L, Singer M (2002). "Terlipressin for norepinephrine-resistant septic shock". Lancet. 359 (9313): 1209–10. doi:10.1016/S0140-6736(02)08225-9. PMID 11955542.
Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón J, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J (2000). "Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome". J Hepatol. 33 (1): 43–8. doi:10.1016/S0168-8278(00)80158-0. PMID 10905585.
Ioannou G, Doust J, Rockey D (2003). Ioannou GN (ed.). "Terlipressin for acute esophageal variceal hemorrhage". Cochrane Database Syst Rev (1): CD002147. doi:10.1002/14651858.CD002147. PMC 7017851. PMID 12535432.
"{1} And {2} Report Fast Track Designation For Terlipressin In Type 1 Hepatorenal Syndrome - News, Search Jobs, Events".
"Drug Product Search". Archived from the original on 2008-07-14.
http://www.medsafe.govt.nz/profs/datasheet/g/Glypressin01mgmlFerringinj.pdf
https://www.drugs.com/international/terlipressin.htmll

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Kam, P. C. A.; Williams, S.; Yoong, F. F. Y. (2004). "Vasopressin and terlipressin: pharmacology and its clinical relevance". Anaesthesia. 59 (10): 993–1001. doi:10.1111/j.1365-2044.2004.03877.x. ISSN 1365-2044.

[OBrien-2] O'Brien A, Clapp L, Singer M (2002). "Terlipressin for norepinephrine-resistant septic shock". Lancet. 359 (9313): 1209–10. doi:10.1016/S0140-6736(02)08225-9. PMID 11955542.

[Uriz-3] Uriz J, Ginès P, Cárdenas A, Sort P, Jiménez W, Salmerón J, Bataller R, Mas A, Navasa M, Arroyo V, Rodés J (2000). "Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome". J Hepatol. 33 (1): 43–8. doi:10.1016/S0168-8278(00)80158-0. PMID 10905585.

[Ioannou-4] Ioannou G, Doust J, Rockey D (2003). Ioannou GN (ed.). "Terlipressin for acute esophageal variceal hemorrhage". Cochrane Database Syst Rev (1): CD002147. doi:10.1002/14651858.CD002147. PMC 7017851. PMID 12535432.

[5] "{1} And {2} Report Fast Track Designation For Terlipressin In Type 1 Hepatorenal Syndrome - News, Search Jobs, Events".

[6] "Drug Product Search". Archived from the original on 2008-07-14.

[7] ttp://www.medsafe.govt.nz/profs/datasheet/g/Glypressin01mgmlFerringinj.pdf

[8] ttps://www.drugs.com/international/terlipressin.htmll

Terlipressin

Availability

Contraindications

See also

References